Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers

Translational Research

Volumn 157, Issue 5, 2011, Pages 265-272

  Ziliak, Dana ^a   O'Donnell, Peter H ^a   Im, Hae Kyung ^a   Gamazon, Eric R ^a   Chen, Peixian ^a   Delaney, Shannon ^a   Shukla, Sunita ^a   Das, Soma ^a   Cox, Nancy J ^a   Vokes, Everett E ^a   Cohen, Ezra E W ^a   Dolan, M Eileen ^a   Huang, R Stephanie ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUOROURACIL; GEFITINIB; HYDROXYUREA; ORGANIC CATION TRANSPORTER; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL SURVIVAL; CHEMORADIOTHERAPY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 79954535834     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2011.01.005     Document Type: Article

References (33)

1. R.S. Huang, S. Duan, and W.K. Bleibel A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity Proc Natl Acad Sci U S A 104 2007 9758 9763 (Pubitemid 47175340)
2. S. Shukla, and M. Dolan Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies Pharmacogenomics 6 2005 303 310 (Pubitemid 40601633)
3. International HapMap Consortium A haplotype map of the human genome Nature 437 2005 1299 1320
4. A. Daly Genome-wide association studies in pharmacogenomics Nat Rev Genet 11 2010 241 246
5. S. Marur, and A. Forastiere Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer Curr Opin Oncol 22 2010 206 211
6. D. Rosenthal, and A. Blanco Head and neck squamous cell carcinoma: optimizing the theraputic index Expert Rev Anticancer Ther 5 2005 501 514 (Pubitemid 40894981)
7. K. Choe, J. Salama, and K. Stenson Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer Raidother Oncol 97 2010 318 321
8. M. Kies, F. Holsinger, and J. Lee Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial J Clin Oncol 28 2010 8 14
9. A. Chan, P. Sanghera, and B. Choo hypofractionated accelerated raidotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck Clin Oncol 23 2010 34 39
10. M. Barkati, B. Fortin, and D. Soulires Concurrant chemoradiation with carboplatin-5-fluorouracil versus cisplatin in locallly advanced oropharyngeal cancers: is more always better? Int J Radiat Oncol Biol Phys 76 2010 410 416
11. E. Cohen, D. Haraf, and R. Kunnavakkam Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer J Clin Oncol 28 2010 3336 3343
12. R.S. Huang, S. Duan, E.O. Kistner, H.M. Christine, and M.E. Dolan Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans Mol Cancer Ther 7 2008 3038 3046
13. R.S. Huang, S. Duan, and S.J. Shukla Identification of genetic variants contributing to cisplatin-induced cytotoxicity using a genome-wide approach Am J Hum Genet 81 2007 427 437 (Pubitemid 47330203)
14. E.R. Gamazon, W. Zhang, and A. Konkashbaev SCAN: SNP and copy number annotation Bioinformatics 26 2010 259 262
15. P.H. O'Donnell, E. Gamazon, and W. Zhang Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants Pharmacogenet Genomics 20 2010 327 337
16. J. Storey, and R. Tibshirani Statistical significance for genomewide studies Proc Natl Acad Sci U S A 100 2003 9440 9445 (Pubitemid 37033947)
17. A. Dabney, J.D. Storey, and G.R. Warnes qvalue: Q-value estimation for false discovery rate control R package version 1.20.0 2009
18. J.D. Storey, and R. Tibshirani Statistical significance for genome-wide studies Proc Natl Acad Sci U S A 100 2003 9440 9445
19. S.J. Shukla, S. Duan, X. Wu, J.A. Badner, K. Kasza, and M.E. Dolan Whole-genome approach implicates CD44 in cellular resistance to carboplatin Hum Genomics 3 2009 128 142
20. E. Gamazon, R.S. Huang, N.J. Cox, and M.E. Dolan Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci Proc Natl Acad Sci U S A 107 2010 9287 9292
21. Y. Zhang, H. Li, and H. Wu Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma Cancer Lett 275 2009 277 284
22. J. Weiske, and O. Huber The histidine triad protein Hint1 triggers apoptosis independent of its enzymatic activity J Biol Chem 281 2006 27356 27366 (Pubitemid 44401763)
23. K. Jackson, Q. Chen, J. Chen, S. Affen, K. Kendler, and X. Chen Association of the histadine-triad nucleotide-binding protein-1 (HINT1) gene variants with nicotine dependence Pharmacogenomics 2010 [Epub ahead of print].
24. Q. Chen, X. Wang, F. O'Neill, D. Walsh, K. Kendler, and X. Chen Is the histadine triad nucleotide-binding protein 1 (HINT1) gene a candidate for schizophrenia Schizophr Res 106 2008 200 207
25. H. Saito Pathophysical regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications Pharmacol Ther 125 2010 79 91
26. C. Lancaster, C. Hu, and R. Franke Cisplatin-induced downregulation of OCTN2 affects carnitine wasting Clin Cancer Res 16 2010 4789 4799
27. R. Franke, A. Kosloske, and C. Lancaster Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase Clin Cancer Res 16 2010 4198 4206
28. T. Toyohara, T. Suzuki, and R. Morimoto SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation J Am Soc Nephrol 20 2009 2546 2555
29. A. Galea, and V. Murray The interaction of cisplatin and analogues with DNA in reconstituted chromatin Biochim Biophys Acta 1579 2002 142 152 (Pubitemid 35341436)
30. B. Wu, P. Dröge, and C. Davey Site selectivity of platinum anticancer therapeutics Nat Chem Biol 4 2008 110 112
31. J. Hoskins, R. Goldberg, P. Qu, J. Ibrahim, and H. McLeod UGT1A128 genotype and irinotecan-induced neutropenia: dose matters J Natl Inst 99 2007 1290 1295 (Pubitemid 47394168)
32. S. Marsh, J. Paul, C. King, G. Gifford, H. McLeod, and R. Brown Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer J Clin Oncol 25 2007 4528 4535 (Pubitemid 350035308)
33. M. Quintela-Fandino, J. López, and R. Hitt Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support J Clin Oncol 24 2006 3611 3618 (Pubitemid 46630534)